Aging and Development of Ovarian Epithelial Carcinoma: The Relevance of Changes in Ovarian Stromalandrogen Production

  • Margaret A. Thompson
  • Mark D. Adelson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 330)


There are three types of ovarian neoplasms: (1) Those which arise from the surface epithelium covering the ovary. (2) Those which are derived from the cortical mesenchymal stroma. (3) Those which develop from germ cells. Our laboratory has concentrated its effort on solid tumors in women of the first type, epithelial, which has the highest incidence and is the most lethal. Development of these tumors is correlated with aging in the ovary. They form primarily during the perimenopause. Among women, 64% of the total ovarian cancer cases are diagnosed between ages 41 and 60 years1. Our approach has been to establish stable tumor cell lines from patient specimens for use as in vitro models. We have investigated the response of these cells to steroid hormones because we hypothesized that these tumors retain some metabolic characteristics which are specific to the ovary. Our data demonstrate that testosterone and androstenedione, but not cortisol, inhibited proliferation of ovarian tumor cells in vitro by a mechanism which was independent of steroid receptors. These androgens are routinely synthesized and secreted by human ovary, and in the menopausal ovary the primary source of androgen is the stromal cell compartment. Because a relatively high local concentration of ovarian androgen exists in vivo, it is possible that androgen may suppress ovarian epithelial carcinoma in women as well. If it does, then development of this carcinoma may be facilitated when the postmenopausal ovary fails to produce adequate androgen during postreproductive years.


Ovarian Cancer Ovarian Carcinoma Ovarian Cancer Cell Ovarian Cancer Cell Line Borderline Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zaloudek, C. The Ovary. In: Gompel, C. and S. G. Silverberg, S. G. (eds.) Pathology In Gynecology And Obstetrics. J. B. Lippincott Company, Philadelphia (1985).Google Scholar
  2. 2.
    Young, J. L., Jr., Percy, C. L. and Asire, A. J. “Surveillance, epidemiology and end results: incidence and mortality data”, 1973–1977. National Cancer Institute Monograph 57, DHHS no. (NIH) 81–2330. U. S. Government Printing Office, Washington, DC. pp 50-51 (1981).Google Scholar
  3. 3.
    Day, T. G. Jr. and Smith, J. P. Diagnosis and staging of ovarian cancer. Semin Oncol. 2:217 (1975).PubMedGoogle Scholar
  4. 4.
    Smith, E. M. and Anderson, B. The effects of symptom and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 56:2727 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    Hacker, N. F., Berek, J. S., Laguasse, L. D., Nieberg, R. K. and Elashoff, R. M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61:413 (1983).PubMedGoogle Scholar
  6. 6.
    Adelson, M. D., Baggish, M. S., Seifer, D. B., Cassell, S. L. and Thompson, M. A. Cytoreduction of ovarian cancer with the Cavitron Ultrasonic Surgical Aspirator, Obstet. Gynecol. 72:140 (1988).PubMedGoogle Scholar
  7. 7.
    Brenner, D. E. and Greco, F. A. Multiagent chemotherapy in advanced ovarian carcinoma. In: Alberts, D. S. and Surwit, E. A. (eds.) Ovarian Cancer. Martinus Nijhoff, Boston, pp 147 (1985).CrossRefGoogle Scholar
  8. 8.
    Louie, K., Ozols, R., Myers, C., Ostechega, Y., Jenkins, J. and Howser, D. Long-term results of a cisplatin containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J. Clin. Oncol. 4:1579 (1986).PubMedGoogle Scholar
  9. 9.
    Bourhis, J., Goldstein, L. J., Riou, G., Pastan, I., Gottesman, M. M. and Benard, J. Expression of a human multidrug reisistance gene in ovarian carcinomas. Cancer Res. 49:5062 (1989).PubMedGoogle Scholar
  10. 10.
    Slotman, B. J. Rationale For The Use Of Endocrine Therapy In Ovarian Cancer. Thesis Publishers, Amsterdam (1990).Google Scholar
  11. 11.
    Kuhnel, R.. de Graaff, J., Rao, B. R. and Stolk, J. G. Androgen receptor predominance in human ovarian carcinoma. J. Steroid Biochem. 26:393 (1987).PubMedCrossRefGoogle Scholar
  12. 12.
    Kuhnel, R., Rao, B. R., Poels, L. G., Delemarre, J. F. M., Kenemans, P. and Stolk, J. G. Multiple parameter analysis of ovarian cancer: Morphology, immunohistochemistry, steroid hormone receptors and aromatase. Anticancer Res. 8:281 (1988).PubMedGoogle Scholar
  13. 13.
    Thompson, M. A., Adelson, M. D., Kaufman, L. M., Marshall, L. D. and Coble, D. A. Aromatization of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma. Cancer Res. 48:6491 (1988).PubMedGoogle Scholar
  14. 14.
    Kuhnel, R., Delemarre, J. F. M., Rao, B. R. and Stolk, J. G. Correlation of aromatase activity and steroid receptors in human ovarian carcinoma. Anticancer Res. 6:889 (1986).PubMedGoogle Scholar
  15. 15.
    Plotz, E. J., Wiener, M. and Stein, A. A. Steroid synthesis in cystadenocarcinoma of the ovaries. Am. J. Obstet. Gynecol. 94:189 (1966).PubMedGoogle Scholar
  16. 16.
    Plotz, E. J., Wiener, M., Stein, A. A. and Hahn, B. D. Enzymatic activities related to steroid synthesis in common ovarian cancer. Am. J. Obstet. Gynecol. 97:1050 (1967).PubMedGoogle Scholar
  17. 17.
    Hughesdon, P. E. Thecal and allied reactions in epithelial ovarian tumors. J. Obstet. Gynecol. Br. Emo. 63:702 (1958).CrossRefGoogle Scholar
  18. 18.
    McNatty, K. P., Smith, D. M., Makris, A., DeGrazia, D. Tulchinsky, C., Osathanondh, R., Schiff, I. and Ryan, K. J. The intraovarian sites of androgen and estrogen formation in women with normal and hyperadrogenic ovaries as judged by in vitro experiments. J. Clin. Endocrinol. Metab. 50:755 (1980).PubMedCrossRefGoogle Scholar
  19. 19.
    Longcope, C., Hunter, R. and Franz, C. Steroid secretion by the postmenopausal ovary. Am. J. Obstet. Gynecol. 138:564 (1980).PubMedGoogle Scholar
  20. 20.
    Judd, H. Hormonal dynamics associated with the menopause. Clin. Obstet. Gynecol. 19:775 (1976).PubMedCrossRefGoogle Scholar
  21. 21.
    Freedman, R. S., Pihl, E., Kusyk, C., Gallager, H. S. and Rutledge, F. Characterization of an ovarian carcinoma cell line. Cancer 42:2352 (1978).PubMedCrossRefGoogle Scholar
  22. 22.
    Tseng, L., Mazella, J., Mann, W. J. and Chumas, J. Estrogen synthesis in normal and malignant human endometrium. J. Clin. Endocrinol. Metab. 55:1029 (1982).PubMedCrossRefGoogle Scholar
  23. 23.
    Cole, P. A. and Robinson, C. H. A peroxide model reaction for placental aromatase, J. Am. Chem. Soc. 110:1284 (1988).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Margaret A. Thompson
    • 1
  • Mark D. Adelson
    • 1
  1. 1.Department of Obstetrics and GynecologyS.U.N.Y. Health Science CenterSyracuseUSA

Personalised recommendations